Literature DB >> 22709255

Targeting the PI3K pathway for cancer therapy.

Navid Sadeghi1, David E Gerber.   

Abstract

The PI3K pathway plays an important role in key cellular functions such as cell growth, proliferation and survival. Genetic and epigenetic alterations in different pathway components lead to aberrant pathway activation and have been observed in high frequencies in various tumor types. Consequently, significant effort has been made to develop antineoplastic agents targeting different nodes in this pathway. Additionally, PI3K pathway status may have predictive and prognostic implications, and may contribute to drug resistance in tumor cells. This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709255      PMCID: PMC4276042          DOI: 10.4155/fmc.12.56

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  187 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene.

Authors:  K Inukai; M Anai; E Van Breda; T Hosaka; H Katagiri; M Funaki; Y Fukushima; T Ogihara; Y Yazaki; Y Oka; T Asano
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

Review 3.  Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.

Authors:  Janet E Dancey; Jose Monzon
Journal:  Future Oncol       Date:  2011-07       Impact factor: 3.404

4.  Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Vienna Ludovini; Fortunato Bianconi; Lorenza Pistola; Rita Chiari; Vincenzo Minotti; Renato Colella; Dario Giuffrida; Francesca Romana Tofanetti; Annamaria Siggillino; Antonella Flacco; Elisa Baldelli; Daniela Iacono; Maria Grazia Mameli; Antonio Cavaliere; Lucio Crinò
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

5.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.

Authors:  R J DeFatta; C A Nathan; A De Benedetti
Journal:  Laryngoscope       Date:  2000-06       Impact factor: 3.325

7.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

9.  Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.

Authors:  Charles T Miller; Justin R Moy; Lin Lin; Matthew Schipper; Daniel Normolle; Dean E Brenner; Mark D Iannettoni; Mark B Orringer; David G Beer
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  27 in total

1.  Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Authors:  Franziska Maria Ippen; Julia Katharina Grosch; Megha Subramanian; Benjamin Macfarlane Kuter; Bianca M Liederer; Emile G Plise; Joana Liliana Mora; Naema Nayyar; Stephen Paul Schmidt; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla Kaliopi Brastianos
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 2.  Chemical modulation of glycerolipid signaling and metabolic pathways.

Authors:  Sarah A Scott; Thomas P Mathews; Pavlina T Ivanova; Craig W Lindsley; H Alex Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-15

3.  Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.

Authors:  Yaongamphi Vashum; Riya Premsingh; Amuthavalli Kottaiswamy; Mathangi Soma; Abirami Padmanaban; Parkavi Kalaiselvan; Shila Samuel
Journal:  Mol Biol Rep       Date:  2020-12-08       Impact factor: 2.316

4.  The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.

Authors:  Franziska M Ippen; Christopher A Alvarez-Breckenridge; Benjamin M Kuter; Alexandria L Fink; Ivanna V Bihun; Matthew Lastrapes; Tristan Penson; Stephen P Schmidt; Gregory R Wojtkiewicz; Jianfang Ning; Megha Subramanian; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla K Brastianos
Journal:  Clin Cancer Res       Date:  2019-02-22       Impact factor: 12.531

Review 5.  The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.

Authors:  Qinyi Wang; Junmin Wang; Hongjiao Xiang; Peilun Ding; Tao Wu; Guang Ji
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 6.  Mechanisms of Natural Extracts of Andrographis paniculata That Target Lipid-Dependent Cancer Pathways: A View from the Signaling Pathway.

Authors:  Ruth Naomi; Hasnah Bahari; Zhi Yi Ong; Yong Yoke Keong; Hashim Embong; Retnagowri Rajandram; Soo Huat Teoh; Fezah Othman; Rosnani Hasham; Khoo Boon Yin; Priyatharisni Kaniappan; Muhammad Dain Yazid; Zainul Amiruddin Zakaria
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

7.  A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.

Authors:  Xiang Wang; Jia-peng Li; Yan Yang; Jian Ding; Ling-hua Meng
Journal:  Acta Pharmacol Sin       Date:  2013-07-29       Impact factor: 6.150

8.  Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.

Authors:  Judit Molnár; Csilla Fazakas; János Haskó; Orsolya Sipos; Krisztina Nagy; Ádám Nyúl-Tóth; Attila E Farkas; Attila G Végh; György Váró; Péter Galajda; István A Krizbai; Imola Wilhelm
Journal:  Cell Adh Migr       Date:  2015-12-08       Impact factor: 3.405

9.  The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.

Authors:  Cedric Tehranian; Laura Fankhauser; Patrick N Harter; Colin D H Ratcliffe; Pia S Zeiner; Julia M Messmer; Dirk C Hoffmann; Katharina Frey; Dana Westphal; Michael W Ronellenfitsch; Erik Sahai; Wolfgang Wick; Matthia A Karreman; Frank Winkler
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

10.  Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.

Authors:  Marjorie G Zauderer; Evan W Alley; Johanna Bendell; Enrica Capelletto; Todd M Bauer; Sophie Callies; Anna M Szpurka; Suhyun Kang; Melinda D Willard; Volker Wacheck; Anna M Varghese
Journal:  Invest New Drugs       Date:  2021-03-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.